scholarly journals NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor

Oncotarget ◽  
2016 ◽  
Vol 7 (6) ◽  
pp. 6774-6789 ◽  
Author(s):  
Caroline Brand ◽  
Christoph Schliemann ◽  
Janine Ring ◽  
Torsten Kessler ◽  
Sebastian Bäumer ◽  
...  
Keyword(s):  
Tissue Factor ◽  
Anticancer Therapy ◽  
Tumor Vessel ◽  
Ng2 Proteoglycan

Anticancer Therapy by Tumor Vessel Infarction with Polyethylene Glycol Conjugated Retargeted Tissue Factor

2013 ◽  
Vol 56 (6) ◽  
pp. 2337-2347 ◽  
Author(s):  
Christian Schwöppe ◽  
Caroline Zerbst ◽  
Max Fröhlich ◽  
Christoph Schliemann ◽  
Torsten Kessler ◽  
...  
Keyword(s):  
Polyethylene Glycol ◽  
Tissue Factor ◽  
Anticancer Therapy ◽  
Tumor Vessel

Low-Energy Ultrasound Treatment Improves Regional Tumor Vessel Infarction by Retargeted Tissue Factor

2015 ◽  
Vol 34 (7) ◽  
pp. 1227-1236 ◽  
Author(s):  
Caroline Brand ◽  
Stefanie Dencks ◽  
Georg Schmitz ◽  
Mareike Mühlmeister ◽  
Jörg Stypmann ◽  
...  
Keyword(s):  
Tissue Factor ◽  
Low Energy ◽  
Ultrasound Treatment ◽  
Tumor Vessel

Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF–NGR using multi-modal imaging

Angiogenesis ◽  
2013 ◽  
Vol 17 (1) ◽  
pp. 235-246 ◽  
Author(s):  
Thorsten Persigehl ◽  
Janine Ring ◽  
Christoph Bremer ◽  
Walter Heindel ◽  
Richard Holtmeier ◽  
...  
Keyword(s):  
Tissue Factor ◽  
Invasive Monitoring ◽  
Tumor Vessel ◽  
Non Invasive

scholarly journals Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13—Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5880
Author(s):  
Mirjam Gerwing ◽  
Tobias Krähling ◽  
Christoph Schliemann ◽  
Saliha Harrach ◽  
Christian Schwöppe ◽  
...  
Keyword(s):  
Tissue Factor ◽  
Malignant Disease ◽  
Volume Fraction ◽  
Multiparametric Mri ◽  
Tumor Perfusion ◽  
Tumor Vessel ◽  
Early Assessment ◽  
Imaging Protocol ◽  
Therapy Initiation ◽  
Adc Values

Early assessment of target hit in anti-cancer therapies is a major task in oncologic imaging. In this study, immediate target hit and effectiveness of CD13-targeted tissue factor tTF-NGR in patients with advanced malignant disease enrolled in a phase I trial was assessed using a multiparametric MRI protocol. Seventeen patients with advanced solid malignancies were enrolled in the trial and received tTF-NGR for at least one cycle of five daily infusions. Tumor target lesions were imaged with multiparametric MRI before therapy initiation, five hours after the first infusion and after five days. The imaging protocol comprised ADC, calculated from DWI, and DCE imaging and vascular volume fraction (VVF) assessment. DCE and VVF values decreased within 5 h after therapy initiation, indicating early target hit with a subsequent decrease in tumor perfusion due to selective tumor vessel occlusion and thrombosis induced by tTF-NGR. Simultaneously, ADC values increased at five hours after tTF-NGR administration. In four patients, treatment had to be stopped due to an increase in troponin T hs, with subsequent anticoagulation. In these patients, a reversed effect, with DCE and VVF values increasing and ADC values decreasing, was observed after anticoagulation. Changes in imaging parameters were independent of the mean vessel density determined by immunohistochemistry. By using a multiparametric imaging approach, changes in tumor perfusion after initiation of a tumor vessel occluding therapy can be evaluated as early as five hours after therapy initiation, enabling early assessment of target hit.

Sign in / Sign up

Export Citation Format

Share Document